Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for Vincristine Sulfate

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            University of Birmingham

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vincristine Sulfate,Carboplatin,Etoposide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding May 21, 2020

            Details:

            The ten year SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) is a Phase III clinical trial designed to evaluate potential treatment pathways for children identified with the disease.